Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors
about
Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 proteaseExtreme Entropy–Enthalpy Compensation in a Drug-Resistant Variant of HIV-1 ProteaseStatistical potentials for fold assessment.Proteochemometric modeling of HIV protease susceptibility.Genotypic testing for human immunodeficiency virus type 1 drug resistance.Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infectionResidues crucial for maintaining short paths in network communication mediate signaling in proteinsResidue centrality, functionally important residues, and active site shape: analysis of enzyme and non-enzyme families.Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavirThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.Probing the role of parasite-specific, distant structural regions on communication and catalysis in the bifunctional thymidylate synthase-dihydrofolate reductase from Plasmodium falciparumCooperative effects of drug-resistance mutations in the flap region of HIV-1 protease.Looking at the proteases from a simple perspective.A PDZ domain-based assay for measuring HIV protease activity: assay design considerations.Potential of small-molecule fungal metabolites in antiviral chemotherapy.Resistance profiles of cyclic and linear inhibitors of HIV-1 protease.Effectiveness of commercial inhibitors against subtype F HIV-1 protease.
P2860
Q27637329-E1FFE9CD-F299-4A0D-A7D7-B78E4ED06BAAQ27681237-1CA9E045-45FC-468F-8807-6A6A55149031Q30329417-8BB075EB-CB51-4316-A5B8-267723540357Q33327559-B2C6E6EA-072B-4870-9D2A-CEE21ABA16BAQ33906239-7B4046B9-5BAD-4AD5-8C9A-D8E0A291F824Q35104695-534D25F6-802A-42EE-803C-595443B8D0C0Q35193500-07A46149-2D08-49C8-9D0D-1195D6963FBBQ36458637-9C8D9481-C39B-4DBC-87AC-F4004815399DQ36841895-439AB865-5029-4900-8F88-C11BCFE890A0Q37018369-785B3810-23D5-48CE-9FEC-BC1778011772Q37093847-EF6ECF32-76B1-441C-B499-5841C279B3B3Q37136020-11F6091A-7263-4BE7-8881-AAF9F76301B2Q37247555-689A585C-7708-4B20-B5E1-12EE0BD732C2Q37848282-09910E11-9722-4600-8DD8-CA2EFD1D67FCQ38357552-64769087-3B20-4A07-B2C8-ED03AA3EE317Q39453829-5A713E71-17C3-4E96-9AAC-8797D37E1E33Q44103468-011B8457-B3CE-4B57-8561-063E7D671F11Q46339842-BD8AFB1F-D49A-4A7C-907A-17F8EA451138
P2860
Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@ast
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@en
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@nl
type
label
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@ast
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@en
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@nl
prefLabel
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@ast
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@en
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@nl
P2093
P2860
P356
P1476
Non-active site changes elicit ...... e HIV-1 protease to inhibitors
@en
P2093
A L vanOlden
C A Rutkowski
H B Schock
M W Stahlhut
P2860
P304
P356
10.1074/JBC.274.34.23699
P407
P577
1999-08-20T00:00:00Z